News >

Medivation Acquires BioMarin's PARP Inhibitor Talazoparib

Silas Inman @silasinman
Published: Tuesday, Aug 25, 2015

David Hung, MD

David Hung, MD

Medivation has announced that it will purchase the PARP inhibitor talazoparib (BMN-673) from BioMarin Pharmaceutical for 0 million, with additional milestone and royalty payments of up to 0 million. Once the agreement closes, Medivation will become responsible for all global research, development, regulatory, and commercialization costs.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication